CORPORATE PRESENTATION

2776 University DriveCoral Springs, FL USA

Phone: (954) 509-0911Fax: (877) 895-5647

investor.relations@NutraPharma.com www.NutraPharma.com

September 2010

NU

TR

A P

HA

RM

A C

OR

PO

RA

TIO

NSAFE HARBOR

Statements made in the course of this presentation that state the

Company’s or management’s intentions, hopes, beliefs, expectations or

predictions of the future are forward-looking statements. It is important to

note that the Company’s actual results could differ materially from those

projected in such forward-looking statements. Additional information

concerning factors that could cause actual results to differ materially from

those in the forward-looking statements is contained from time to time in

the Company’s SEC filings, including but not limited to the Company’s

report on Form 10-K for the year ended December 31, 2009; the Company’s

report on Form 10-Q for the quarter ended June 30, 2010. Copies of these

filings may be obtained by contacting the Company or the SEC.

OVERVIEW

Nutra Pharma is a biotechnology company specializing

in the acquisition, licensing and commercialization of

pharmaceutical products and technologies for the

management of neurological disorders, cancer,

autoimmune and infectious diseases.

NU

TR

A P

HA

RM

A O

VE

RV

IEW

INTRODUCTION

Nutra Pharma, through its subsidiaries, carries out basic drug discovery

research and clinical development. The Company also manufactures,

through its subsidiary over-the-counter (OTC) drug products for the

treatment of moderate to severe chronic pain. These pain relievers are sold

under the brands Cobroxin and Nyloxin.

Drug Development

In addition to manufacturing Cobroxin and Nyloxin, ReceptoPharm is also developing proprietary therapeutic

protein products primarily for the prevention and treatment of viral and neurological diseases, including

Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and

pain in humans. Outside of its role as the drug discovery arm for Nutra Pharma, ReceptoPharm provides

contract research services through its ISO class 5 and GMP certified facilities.

Medical Devices

Designer Diagnostics is the wholly-owned medical devices subsidiary of Nutra Pharma. The Company was

established in 2005 for the marketing and sales of rapid diagnostics test kits for infectious diseases,

including Nontuberculous Mycobacteria (NTM) and Tuberculosis (TB).

NU

TR

A P

HA

RM

A O

VE

RV

IEW

MANAGEMENT TEAM

Name

Rik J. Deitsch Chairman and Chief Executive Officer, Nutra Pharma

Paul F. Reid, Ph.D. Chief Executive Officer, ReceptoPharm

Neil Roth President, Designer Diagnostics

NU

TR

A P

HA

RM

A O

VE

RV

IEW

BOARD OF DIRECTORS

Name

Rik J. Deitsch Chairman and Chief Executive Officer, Nutra Pharma

Harold H. Rumph Director

Dr. Stewart Lonky, MD Director

Garry R. Pottruck Director

MARKETED PAIN RELIEVERS

Nutra Pharma manufactures and markets over-the-

counter (OTC) drug products for the treatment of

moderate to severe chronic pain. These products are

sold under the Cobroxin and Nyloxin brands.

PA

IN P

RO

DU

CT

SCOBROXIN OVERVIEW

Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven

to treat Stage 2 (moderate to severe) chronic pain.

Cobroxin was launched in August 2009 and is available as an oral spray for treating lower back pain,

migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and

pain associated with repetitive stress and arthritis.

Additional Benefits to Cobroxin Include:

• All Natural

• Non-Addictive

• Non-Narcotic

• Non-Opiate

• Long Lasting

PA

IN P

RO

DU

CT

SCOBROXIN OVERVIEW

Cobroxin is currently sold at the following retailers:

PA

IN P

RO

DU

CT

SNYLOXIN OVERVIEW

Nyloxin is available an over-the-counter (OTC) pain reliever clinically

proven to treat Stage 2 (moderate to severe) and Stage 3 (severe) chronic

pain.

Nyloxin was launched in mid-2010 as an oral spray for treating back pain, neck pain, headaches, joint pain,

migraines, and neuralgia, and as topical gel for treating joint pain, arthritis pain and pain from repetitive stress.

Nyloxin is available in both everyday strength and extra strength.

PA

IN P

RO

DU

CT

SMARKET POTENTIAL

Pain is the single most common reason patients seek medical care and

accounts for half of all physician office visits in the United States.

According to the American Pain Foundation, each year, more than 25 million people in the United States

experience acute pain as a result of injury or surgery. Additionally, more than 50 million people in the United

States are affected by ongoing chronic pain.

Both Cobroxin and Nyloxin:

1. Make potent pain relief accessible to:

• People without healthcare insurance (42 million)

• People without prescription coverage

• People afraid of opiate side effects

• People subject to drug screening for work

• People for whom OTC NSAIDs didn’t work and are just living with the pain

• Doctors afraid to prescribe opiates

2. Target consumers not well-served by current products

DRUG DISCOVERY

Nutra Pharma’s wholly-owned drug discovery

subsidiary, ReceptoPharm, conducts research into a

number of products with applications for neurological,

immunological, autoimmune and viral conditions.

DR

UG

DIS

CO

VE

RY

DRUG DISCOVERY OVERVIEW

Nutra Pharma’s wholly-owned subsidiary, ReceptoPharm, is developing

proprietary therapeutic protein products for the billion-dollar biologics

market. The Company has two leading drug candidates: RPI-MN and RPI-

78M.

RPI-MN

RPI-MN inhibits the entry of several viruses that are known to cause severe neurological damage in such

diseases as encephalitis and Human Immunodeficiency Virus (HIV). It is being developed first for the

treatment of HIV.

RPI-78M

RPI-78M is being developed for the treatment of Multiple Sclerosis (MS) and Adrenomyeloneuropathy

(AMN). Other neurological disorders that may be served by RPI-78M include Myasthenia Gravis (MG) and

Amyotrophic Lateral Sclerosis (ALS).

RPI-78M and RPI-MN contain anticholinergic peptides that recognize the same receptors as nicotine

(acetylcholine receptors) but have the opposite effect. In a specific chemical process unique to

ReceptoPharm, the drugs are created through a process of chemical modification.

DR

UG

DIS

CO

VE

RY

BENEFITS OF RPI-MN AND RPI-78M

RPI-MN and RPI-78M possess several desirable properties as drugs:

1. They lack measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells.

This means that patients cannot overdose.

2. They display no serious adverse side effects following years of investigations in humans and animals.

3. They are extremely stable and resistant to heat, which gives the drugs a long shelf life. The drugs' stability has

been determined to be over 4 years at room temperature. This is extremely unusual for a biologic drug.

4. They are easy to administer.

5. RPI-78M can be administered orally -- a first for a biologic MS drug. This will present MS patients with additional

quality of life benefits by eliminating the requirement for routine injections.

DR

UG

DIS

CO

VE

RY

SPECIFIC BENEFITS OF RPI-MN

Benefits of Nutra Pharma’s HIV/AIDs Treatment

RPI-MN Fuzeon by Roche/Trimeris

Mutations are not Created Mutations are Created

Relatively Inexpensive Very Expensive – Twice Current Therapies

No Significant Adverse Side Effects Adverse Side Effects Present – Some Severe

Long Shelf Life Limited Shelf Life

Patient Does Not Develop Resistance Patient Develops Immune Resistance

Easy to Manufacture Difficult Manufacturing Leads to Limited Use

DR

UG

DIS

CO

VE

RY

SPECIFIC BENEFITS OF RPI-78M

Benefits of Nutra Pharma’s Multiple Sclerosis (MS) Treatment

RPI-78M Competitive Drugs

Disease Progress Stops Disease Progression Only Slows

Patient Condition Improves No Claims Against Patient Improvement

No Significant Adverse Side Effects Adverse Side Effects Present – Some Severe

Long Shelf Life Limited Shelf Life

Resistant to Heat Requires Refrigeration

Patient Does Not Develop Resistance Patient Develops Immune Resistance

Improves Quality of Life No Evidence for Quality of Life Improvement

DR

UG

DIS

CO

VE

RY

RESEARCH & DEVELOPMENT PIPELINE

ReceptoPharm's research and development pipeline consists of several novel

therapies in various stages of development to prevent and/or treat Multiple

Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy

(AMN), Herpes, Rheumatoid Arthritis (RA) and Pain.

DR

UG

DIS

CO

VE

RY

PUBLISHED RESEARCH

Cobratoxin Inhibits Pain-Evoked Discharge of Neurons in Thalamic Parafascicular

Nucleus in Rats: Involvement of cholinergic and serotonergic systems // Toxicon (April 2009)

Alpha Cobratoxin as a Possible Therapy for Multiple Sclerosis: A Review of the

Literature leading to Its Development for This Application // Critical Reviews™ in Immunology

(Volume 27 / Issue 4 2007)

Analgesic Effects of Receptin, a Chemically Modified Cobratoxin from Thailand Cobra

Venom // Neuroscience Bulletin (September 2006) 

Amelioration of Acute and Relapsing Stages of the Experimental Allergic

Encephalomyelitis by Cobra Toxins // Biomedical Sciences Instrumentation (June 2006)

A Long-Form a-Neurotoxin from Cobra Venom Produces Potent Opioid-Independent

Analgesia // Acta Pharmacologica Sinica (April 2006)

A Short-Chain a-Neurotoxin from Naja naja atra Produces Potent Cholinergic-

Dependent Analgesia // Neuroscience Bulletin (March 2006)

CONTRACT RESEARCH SERVICES

ReceptoPharm has installed the pathways to

develop, produce and supply clinical material for

Phase I and II studies at the highest levels. In

2008, the Company began offering services

catering to small and start-up biotechnology

companies.

CO

NT

RA

CT

RE

SE

AR

CH

SE

RV

ICE

SPARTNERING WITH RECEPTOPHARM

As a clinical stage company specializing in biologics, ReceptoPharm has

cleared many of the hurdles that face emerging biotech companies. Below

are the top reasons that companies choose to partner with ReceptoPharm

as its CRO:

1. Therapeutic experience encompassing infectious disease, autoimmune conditions, neurological disorders

and oncology indications.

2. A renowned team of scientists, led by Dr. Paul Reid, specializing in human and veterinary regulatory

affairs for the United States, Canada, and Europe, and drug applications (pre IND, IND and Orphan),

drug production, new drug development, clinical trial design, patient monitoring, and experimental design.

3. Significant investment in establishing a production facility to meet US and EU standards, including the

installation of quality systems to meet GMP standards and ISO Class 5 certification.

CO

NT

RA

CT

RE

SE

AR

CH

SE

RV

ICE

SA GLOBAL VIEW ON DRUG DEVELOPMENT

ReceptoPharm prides itself on taking a global view on drug development;

whether it’s preparing submissions, protocols, formulations, or organizing

clinical trials internationally.

ReceptoPharm has invested heavily in establishing its own production facility to meet US and EU standards,

including the installation of quality systems to meet GMP standards. Its commitment to maintaining the

highest quality standards can now be used as a resource by other biopharmaceutical companies.

CO

NT

RA

CT

RE

SE

AR

CH

SE

RV

ICE

STOP-RATED DRUG PRODUCTION FACILITIES

Establishing and maintaining a qualified drug production facility can

represent a significant drain on a small company’s resources.

ReceptoPharm understands that its investment in manufacturing and its first-hand knowledge in drug

discovery and development can be very valuable assets to small companies that do not have these

resources or capabilities in-house. Working with ReceptoPharm, through its ISO class 5 and GMP certified

facilities, will allow these companies to avoid considerable clinical development expenses and allow them to

focus on a more important task, expeditiously getting their products to the next stage.

CO

NT

RA

CT

RE

SE

AR

CH

SE

RV

ICE

SPRE-PRODUCTION STUDIES

Stability Studies

Formulation

Adventitious Viral Testing

Preservative Efficacy Testing

Assay Development/Potency Testing

Methods Development

CONTRACT MANUFACTURING SERVICES

US & EU REGULATORY SUPPORT

FDA Drug Applications, IND Preparation

EU Submissions, IMPD Preparation

QUALITY SYSTEMS/GMP CERTIFICATION

Installation of Quality Systems Using Our SOPs

GMP Audits

GMP Training

QA Function

IQ/OQ/PQ

Validations (Equipment and Processes)

STERILE FILLING CAPABILITIES

ReceptoPharm can manually fill a variety of drug

products for your clinical development projects in

the US and EU. While ReceptoPharm specializes in

biologics, including mAbs, natural, recombinant and

synthetic proteins, it can also prepare and fill

pharmaceutical products in its ISO class 5

cleanroom facilities.

Drug Formulation

ISO 5 Sterile Filling Suite, Single and Multi-Dose

Liquids for Injection

Clinical Trial Supplies to FDA & EU Requirements

Packaging and Shipment to Sites

Release Testing and Certification

MEDICAL DEVICES

Nutra Pharma’s wholly-owned drug discovery

subsidiary, Designer Diagnostics, is a biotechnology

sales and marketing company founded for the sale of

diagnostics test kits for infectious diseases.

TE

ST

KIT

TE

CH

NO

LO

GY

LEADING TEST KIT TECHNOLOGY

Designer Diagnostics Test Kits provide a highly cost effective, highly

efficient, low infrastructure solution for identifying and testing sensitivity of

Nontuberculous Mycobacteria (NTM) that are capable of utilizing paraffin

wax as a sole carbon source or those that are hydrophobic. Additionally

Designer Diagnostics provides an efficient solution for the rapid

identification and sensitivity testing of Tuberculosis (TB).Benefits of Test Kit Technology

Ability to Provide Much Earlier Diagnosis (Less than 1 Week)

Long Shelf Life

Can be Stored in Extremely Hostile Environments

Cost Effective Compared to All other Traditional Methods

Does not Require New Large Capital Expenditures

Can be Easily Integrated into Any Lab Environment from the Most Advanced to a Simple Mobile Lab

Results can be Quickly Translated into PCR Testing and Other Antibiotic Sensitivity Testing Techniques

CONTACT NUTRA PHARMA

2776 University DriveCoral Springs, FL 33065

Phone: (954) 509-0911Fax: (877) 895-5647

investor.relations@NutraPharma.com www.NutraPharma.com